IGF-1
|
Promotion of neuronal survival in vitro and in vivo
|
Ang et al., 1992; Hughes et al., 1993
|
Enhancing of axonal sprouting |
Caroni and Grandes, 1990
|
Protection against excessive glutamate and ischemia |
Nakao et al., 2001; Vincent et al., 2004
|
Induction of nerve regeneration |
Kanje et al., 1989
|
|
Effects in MNDs
|
References
|
|
Improved motor functions after intrathecal administration in ALS patients |
Nagano et al., 2005
|
Improved muscle force, motor coordination and survival in SOD1-G93A ALS mice |
Saenger et al., 2012; Wang et al., 2018
|
Reduction of MN degeneration and increase of neuromuscular junction innervation in a SMA mouse model |
Tsai et al., 2014
|
Increased muscle fibers hypertrophy and the number of functionally active axonal sprouts in a SMA mouse model |
Krieger et al., 2014
|
Improving of motor performances, attenuated weight loss and increased survival in a SBMA mouse model |
Rinaldi et al., 2012
|
Amelioration of ionic current defects in a SBMA cell model |
Jimenez Garduno et al., 2017
|
|
Effects on neurons
|
References
|
|
PACAP
|
Promotion of neuronal survival |
Dejda et al., 2011; Manecka et al., 2013
|
Induced in damaged neurons |
Pettersson et al., 2014
|
Promotion of axonal regeneration |
Tsuchida et al., 2014
|
Effects in MNDs
|
|
Neuroprotective action on preganglionic parasympathetic and sympathetic neurons in SOD1-G93A ALS mouse model |
Ringer et al., 2013
|
Increase of cell survival in a ALS cell model |
Maugeri et al., 2019
|
Attenuation of apoptotic signaling in ALS iPSC-derived MNs |
Bonaventura et al., 2018
|
MN protection in SBMA cell and mouse model |
Polanco et al., 2016
|
Amelioration of ionic current defects in a SBMA cell model |
Jimenez Garduno et al., 2017; Martinez-Rojas et al., 2021
|